Printer Friendly

CYTRX CORPORATION LICENSES OPHTHALMIC PATENT FROM BRUJO CORPORATION

 NORCROSS, Ga., Dec. 9 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR) announced today it has licensed a patent for the ophthalmic use of glycosaminoglycans -- the family of compounds that includes CytRx's TherMax(TM) -- for the treatment of conditions that affect the eye.
 TherMax is currently in Phase II development by CytRx for a range of dermatological conditions including burns and inflammatory skin diseases. CytRx has licensed the worldwide rights to the ophthalmic patent (US patent 5,141,928) from Dr. Lawrence Goldman, the inventor of the technology and president of Brujo Corporation located in Austin, Texas.
 Jack J. Luchese, president and chief executive officer of CytRx, said: "This technology is an excellent fit with our TherMax program. We intend to work with partners in the ophthalmic field to rapidly develop and commercialize the prescription and nonprescription applications of the technology to provide value to CytRx shareholders."
 CytRx Corporation is engaged in the research and development of critical care pharmaceutical products for the treatment of vascular and infectious diseases, burns and cancer. Vaxcel(TM), a CytRx subsidiary, is developing an advanced adjuvant system for human and veterinary use. CytRx's Vetlife(TM) subsidiary is developing feed additives to enhance growth in feed animals.
 -0- 12/9/93
 /CONTACT: CytRx Corporation, public relations, 404-368-9500/
 (CYTR)


CO: CytRx Corporation; Brujo Corporation ST: Georgia, Texas IN: MTC SU: LIC

BR-TG -- AT009 -- 2266 12/09/93 14:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 9, 1993
Words:231
Previous Article:PURUS INC. RAISES ADDITIONAL $3 MILLION FROM COMMON STOCK OFFERING
Next Article:CHARTER FEDERAL ANNOUNCES A 1 FOR 5 REVERSE STOCK SPLIT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters